Metastatic lung cancer encompasses a heterogenous group of patients in terms of burdens
of disease, ranging from patients with extensive metastases to those with a limited number of …

More than 50% of NSCLC patients present with metastatic disease at first diagnosis, with a
median survival of 8–11 months. However, selected patients with oligometastatic disease …

A best evidence topic in thoracic surgery was written according to a structured protocol. The
question addressed was whether stereotactic body radiotherapy (SBRT) was equivalent to …

Background Nearly 7% of stage IV Non-Small cell Lung Cancer (NSCLC) patients present
oligometastatic disease at diagnosis. These patients can benefit from definitive treatment to …

Objective In this review, the concept of (synchronous) oligometastatic disease in patients
with non-oncogene-driven non-small cell lung cancer (NSCLC) will be placed in the context …

In recent years, the emergence of the oligometastatic state has called into question whether
patients found to have a limited or low metastatic tumor burden may benefit from locally …

Purpose: Oligometastases was divided into sync-oligometastases and oligo-recurrence, the
difference being that the primary site of oligometastases was uncontrolled (sync …

Abstract Oligometastatic Non-Small Cell Lung cancer (OMD NSCLC) has been proposed to
bridge the spectrum between non-metastatic to widely metastatic states and is perceived as …

Metastasis or recurrence of cancer has been considered as representing a near terminal life
stage. As a result, for a long time, cancer patients with metastasis or recurrence have been …

Oligometastases and oligo‐recurrence are among the most important notions of metastatic
and recurrent cancer. The concept of oligometastases is related to the notion that cancer …